 |
|
 |
 |
|
||||||||||||||
|
FDA approves new smoking cessation drug after delaying
Acomplia The U.S. Food and drug Administration on May 11th approved the second nicotine-free prescription drug for smoking cessation after rejecting Sanofi's application to market acomplia. The drug, Varenicline, has been approved by FDA after bupropion already known as Wellbutrin, rebranded as Zyban. This Pfizer drug shown to help more than one in five smokers quit the habit. Pfizer Inc. plans to market the twice-daily tablet as Chantix. FDA has approved Varenicline within 6 months which is very short duration for the drugs approval. This happened due to its confirmed efficiency. As report is being flashed, The FDA would inform to Sanofi to give the new clinical trial of Acomplia for the further consideration as a smoking cessation drug. The approved course of Chantix treatment is 12 weeks, a period that can be doubled in patients who successfully quit to increase the likelihood they will remain smoke-free, the FDA said.
|
||||||||||||||
